Only Dr Ingvar Bjarnason of Northwick Park Hospital has much experience with it, using 99mTctetraphenyl porphyrine sulphonate (TPPS). He has obtained good correlations with the results of 111indium leukocyte scans in a small series of patients with Crohn's disease, but unreliable results in ulcerative colitis. Other problems awaiting solutions are the heterogeneity of the porphyrin preparation and the difficulty in preparing batches of it consistently.
Scintigraphic demonstration of reflux Surprisingly, work is only just starting on the use of radioisotopes to demonstrate gastro-oesophageal reflux, an exceedingly common condition. One reason may be the advent of 24-hour ambulatory pH monitoring which gives so much information and is probably the gold standard at present. Dr P Isaacs of Blackpool Victoria Hospital finds that when 99mTc-sulphur colloid is swallowed with a mouthful of water and the abdomen is compressed, reflux is detected with a sensitivity of only 73% compared with the pH probe. Doubtless the sensitivity of the test can be improved by modifying the technique, but a test like this will always suffer from one disadvantagethe most it can show is that reflux can occur in a particular, very artificial situation. It cannot tell whether reflux is occurring in a person's day-to-day life. Nevertheless, radionuclide imaging of the oesophagus is attractive because it is so simple. Also, it can be combined with measurement of oesophageal transit time, simply by following the passage of the radioactive bolus down the chest. Research in this field is active and we shall doubtless hear more soon.
The other kind of reflux which can cause dyspeptic symptoms is reflux of bile-rich duodenal fluid into the stomach. Interest in this is high because bile in the stomach leads to gastritis and, possibly, in the long term to gastric ulcer and cancer. Much has been learnt already by tests involving tubes in the stomach and duodenum, but such tests are uncomfortable and may even induce reflux. Only with the use of an isotopic gamma-emitter which is secreted into bile can one study bile reflux under physiological circumstances. Dr Keith Harding of Birmingham is one of many people studying bile reflux using 99mTclabelled diethyl HIDA (imino-diacetic acid) which, after intravenous injection, is rapidly excreted into bile. Gamma-camera imaging picks up reflux of as little as 1% of the injected dose into the stomach.
The test has imperfect reproducibility (75%), but Dr Harding has already made some interesting discoveries. Even normal subjects quite often have bile reflux after a liquid meal containing 20 g fat, and as many as 45% have it after cholecystokinin has been injected to make the gallbladder contract. Contrary to expectations, reflux was no more common in patients with gastric ulcer than in controls, nor was it especially common in gallstone patients who complained of flatulent dyspepsia. Curiously the presence of a radiologically non-functioning gallbladder was associated with a high incidence of reflux.
As research tools, radioisotopes undoubtedly have a great future in gastroenterology, and in the last talk of the day Dr Nick Read from Sheffield described how he has used 99mTc sulphur colloid to follow the progress of a normal meal through the gut and reported some of his many interesting findings on factors governing this progress.
To what extent the tests described will be used in the district general hospital in the future remains to be seen. Some senior gastroenterologists in the audience were sceptical, but my own bet is that some ofthem will find a place. Immunology and molecular biology of schistosomiasis Schistosomiasis remains a widespread disease, prevalent in many parts of the developing world. It is caused by infection with parasitic trematodes, schistosomes, which are transmitted by water snails which inhabit slow-moving rivers, lakes and pools. Infection is characteristically chronic. Enormous numbers of eggs are produced by the adult parasites in the mesenteric or pelvic veins. Some of the eggs lodge in the liver, intestine or urinary tract (depending on the parasite species involved), where they elicit granulomatous reactions and subsequent fibrosis.
Present control measures of schistosomiasis include drug treatment of infected individuals, improved sanitation, health education and the use of molluscicides. However, the widespread develop-ment of irrigation schemes, which encourage the propagation of the intermediate host, may lead to an increase in the number of infected individuals, the current estimate being about 200 million. Since a vaccine to protect against schistosomiasis has been considered as a possible way to control the disease, a considerable research effort has been undertaken in order to attempt to understand schistosome immunity in both man and experimental animals, and to investigate the possible stimulation of protective immunity using attenuated organisms or dead antigenic material in a vaccine. Several important advances in the immunology and molecular biology of schistosomiasis were presented at a meeting of the section of Clinical Immunology. & Allergy on 10 June 1985.
Protective immunity in man During the last decade doubts have been expressed as to whether protective immunity develops after infection in man. Although infection rates are 0141-0768/86/ 050308-04/$02.00/0 o 1986
The Royal Society of Medicine higher in children than in adults, it has been thought that this may be due to reduced contact with schistosome-infected water rather than acquired resistance. Two speakers, Dr Paul Hagan (Medical Research Council, The Gambia) and Dr Anthony Butterworth (Cambridge), discussed epidemiological studies which were designed to resolve this question. Both groups relied upon estimates of an individual's exposure to infective cercariae and related this to their reinfection following drug treatment. The work of Butterworth and his colleagues in Kenya concerned Schistosoma mansoni infection'. Within a group of 129 schoolchildren aged 9-15, 35 showed high levels of water contact at sites containing infected snails and yet showed little or no reinfection during a period of a year following drug treatment. These were considered to be resistant, compared with a group of 22 individuals who became heavily reinfected and were considered to be susceptible. The resistant group was an average of 2.0 years older (within the 6-year age span of the group) than the susceptible group. Resistance thus appeared to be an age-dependent event. The most likely interpretation of these results was that the resistant children had developed acquired immunity2.
Two studies on reinfection with S. haematobium after drug treatment in an endemic area in The Gambia were reported by Dr Hagan. In the first study on children aged 8-13 years, conclusions similar to those in Kenya were reached, namely that some children had developed a degree of resistance to reinfection. The second study involved all age groups within a village and again suggested that water contact patterns by themselves were not able to account for observed levels of reinfection. Children aged 10-15 years were more resistant than those under 10; adults, particularly women, were even more resistant.
Resistance was correlated with various immunological measurements. In The Gambia, children with high peripheral blood eosinophil counts were resistant, as were individuals with high serum titres to adult worm antigens. The two effects were independent. In the Kenyan study, serum antibody titres to egg antigens correlated positively with levels of reinfection. Analysis using rat monoclonal antibodies suggested that the human anti-egg antibodies might block the expression of an otherwise effective immune response. It was suggested that the lack of resistance in young children might be attributable to high levels of such antibodies, which subsequently declined in older individuals, allowing expression of immunity.
Protective immunity in mice
The majority of experimental studies of schistosome immunity have used S. mansoni, which is readily maintained in the laboratory and produces a chronic infection in mice that resembles infection in man'.
The mouse develops partial resistance to reinfection following a primary infection, or following immunization with cercariae attenuated by high levels of irradiation. Immunization with irradiated cercariae is preferred in studies of immunity, since the pathology associated with chronic infection is avoided, and dissection of immune effector mechanisms simplified. Studies on immunity to S. mansoni in mice were discussed by Dr Ron Smithers (Mill Hill). Recent evidence was presented which showed that resistance to reinfection (stimulated by irradiated cercariae) could be ablated by administration of an anti-neutrophil monoclonal antibody at the time of challenge. This antibody had the effect of reducing anamnestic cellular responses, and prevented the formation of local inflammatory responses to invading organisms. These experiments provided further evidence for an immunological basis of resistance to reinfection, and directly implicated inflammatory responses as the basis of this process. Furthermore, it was reported that resistance to reinfection in chronically infected mice was also reduced by administration of the anti-neutrophil monoclonal. It was concluded that similar immune effector mechanisms are involved in immune resistance to schistosome infection, whether stimulated by chronic infection or by immunization with irradiated cercariae.
Dr R A Wilson (York) described the use of radiolabelled schistosomula and autoradiography of compressed organ preparations to study antischistosome immunity4. The lungs were shown to be the major sites in which parasites were eliminated in immunized mice. (Invading schistosomula normally accumulate in the lungs 3-7 days after entering the skin of a host, and then migrate via the vascular system to the liver.) In vaccinated mice, ultrastructural examination of the lungs showed a marked inflammatory response, but there was little evidence for direct cytotoxic damage to the migrating schistosomula. It was suggested that resistance in immunized mice was due to disruption of the intravascular migration of the parasite, rather than direct cytotoxicity.
Although irradiation-attenuated vaccines against animal schistosomes were now undergoing field trials in cattle, there has been concern about possible tissue injury caused by unwanted reactions to whole worm vaccines which could prevent their use in man. Dr Quentin Bickle (London) discussed this, and described recent work on individual larval antigens which could give rise to immunity, with a view to their eventual use as safer vaccines in man. By varying the dose of irradiation given to immunizing cercariae, and terminating infections with an effective drug (Roll-3128), the antigens normally exposed on young schistosomula were-shown to be important in stimulating immunity in mice5. Monoclonal antibodies were raised to these larvel antigens. The antibodies binding to polypeptides of Mr 32K, which is shared with adult worms, and Mr 16K which is stagespecific, were capable of passively transferring resistance to mice6. It was concluded that these parasite antigens could be candidates for making schistosome vaccines.
Dr Stephanie James (Washington DC, USA) described a novel experimental vaccine by which mice were protected against an infective challenge with S. mansoni by prior intradermal injections of schistosomulum or adult worm extracts, with Bacillus Calmette Guerin (BCG)7 8. This immunization protocol gave rise to a parasite-specific delayed hypersensitivity reaction which was thought to be the basis of its success. A Mr 97K soluble polypeptide present in adult worms and schistosomula was partially purified, and it was shown to be able to protect mice in a similar way. This molecule is another important candidate for a S. mansoni vaccine.
Protective immunity in rats Rats develop particularly strong protective immunity against S. mansoni, and do not permit mature chronic schistosome infections. Professor Andre Capron (Lille) discussed how antibodydependent cell cytotoxicity plays an important role in immunity in rats, as judged by passive transfer experiments involving both antibody and cells9. Parasite antigens have been identified which induce immunity in this system, and which could be used in vaccines. In particular, a major schistosomulum surface polypeptide of Mr 38K was shown to be involved in the induction of immunity by the passive transfer of monoclonal antibodies'°. Recently, an antiidiotypic monoclonal antibody was raised against the protective anti-Mr 38K antibody itself, and was shown to act as an internal image of the antigen, as it immunized rats against a subsequent challenge with S. mansoni'1. The importance of this result is that it provides a possible means for producing an effective anti-schistosome vaccine without the need for repeated purification of molecules from the limited amounts of parasite material that can be produced in laboratory-maintained life cycles.
Progress towards vaccines produced from recombinant microorganisms
Another means for making large amounts of antigenic material for use in vaccines, is to prepare it in recombinant microorganisms. Progress in this area was discussed by Dr David Taylor (Cambridge) and Dr Andrew Simpson (Mill Hill) . Dr Taylor reported the identification of several cDNA clones encoding S. mansoni antigen genes using the technique of hybridization selection. Some of these corresponded to schistosomulum surface antigens, but their relationship to antigens known to mediate immunity has not yet been established. Two of the clones encoded antigens recognized more frequently by patients resistant to reinfection than those susceptible to challenge2. One antigen gene encoding a major egg antigen12 has been subcloned into the expression vector PEX2, where it was expressed as a fusion peptide with the antigenic properties of the nascent polypeptide. Dr Simpson described an alternative strategy for preparing recombinant microorganisms producing possible protective antigens. cDNA was cloned directly into the expression vector AGT11 creating a large library (>106) of recombinants. Clones expressing S. mansoni schistosome antigens were detected by screening the library with antibody. Eight clones expressing antigens recognized by anti-surface membrane antibodies, and approximately 20 clones recognized by immune mouse sera were defined. Again, the relationship of these antigens to the protective antigens described by the other speakers at the meeting has not yet been established. Expression libraries of both S. mansoni and S. haematobium cDNA have been constructed. In order to facilitate the identification of genes encoding important surface antigens, two of these -Mr 32K and 20Khave been purified from S. mansoni13"4 and oligonucleotide probes constructed which correspond to partial amino acid sequences. Both Dr Taylor and Dr Simpson pointed out that study of the molecular biology of schistosomes presented other important areas for future work. Both speakers reported the cloning of genes thought to encode major egg constituents which were being used to investigate the control of schistosome oogenesis"5. In addition, Dr Simpson discussed the possibility of using cloned genes and hybridization techniques for the rapid identification of different schistosome strains and species'6.
Conclusions
This meeting showed that there have been several important recent advances in our understanding of schistosome immunity which could lead towards the development of a vaccine for use in man. The demonstration of acquired resistance to reinfection by patients exposed to S. mansoni and S. haematobium is extremely encouraging in this respect. Several schistosome antigens have been found to be capable of inducing immunity, the best described being to the dominant S. mansoni schistosomulum surface antigens of Mr 38K and 32K. Protective immunity can now be induced in uninfected experimental animals with either monoclonal antibodies recognizing these antigens, anti-idiotype antibodies or antigen presented with BCG. It now remains to be seen whether sufficient quantities of these antigens can be produced in vitro, either by gene cloning or peptide synthesis, so that they can be developed for possible use in man.
A J G Simpson AIDS (and STD) prophylaxis: urgent need for an effective genital antiseptic 'Metchnikoff and Roux' method of personal prophylaxis is the first effective, satisfactory method discovered, but it is only the last of innumerable attempts ... All of them have been repudiated, and most of their authors heaped with obloquy, because any method of this sort has been regarded as an encouragement to sexual licence'.
Sir, The above comment by Pusey1 may indeed, judging by the record, identify the reason why research on the control of sexually transmitted diseases (STDs) has concentrated so firmly on therapy, and why initial pursuit of an effective genital antiseptic withered. I have dealt with the history of this debate elsewhere2: it was only when, in 1916, the incidence of STDs in the military became an emergency that the rather crude prophylactics then availablemercury ointment and borated vaselinewere issued to troops. If it had not been for the climate of opinion, the epidemiological results of these primitive methods, which reduced incidence in some leave parties from 20% to 3%, many of these deliberate, would surely have justified energetic pursuit of better agents. One may speculate historically on what the course of STD prevalence would have been if both therapy and local prevention had been addressed in tandem. By the time that public attitudes had become more tolerant, the discovery of antibiotics reduced the incentive to look again at the older work. In fact, antibiotics have been used extensively as prophylactics, with the emergence of resistant strains and the prominence of STDs such as nonspecific urethritis, herpes and chlamydiasis which do not respond to them. The appearance of AIDS and anxiety about its spread by heterosexual intercourse represent the price of neglect. If it were to spread extensively outside high-risk groups, the existing governmental authorities have no strategy to deal with it, beyond recommendations of continence. These may be effective while public anxiety remains high, but neither the introduction of syphilis as a pestilence in 16th century Europe, nor the prevalence of its late effects in 19th century Europe, seem to have effectively deterred risk-taking.
The case for intensified research on a safe, effective and aesthetic genital antiseptic deserves serious reconsideration. We have a public acclimatized by advertising to all manner of sexual cosmetics (lubricants, desensitizers, and deodorants) and one which resorts almost universally, and especially in casual sexual encounters, to contraception, often chemically based or supplemented. Judging by the apparent effectiveness and the unexpectedly low toxicity observed during the era of mercurials, it seems beyond question that modern pharmaceutical chemistry could do very much better in producing bactericidal and viricidal agents for local application which are effective, well tolerated, and capable of incorporation into chemical contraceptives, the lubricants of sheaths, and antiseptic foams and creams. One barrier to commercial research -the formalities required to establish safety and effectiveness for a non-therapeutic product intended for long-term use -could and should be dealt with by direct governmental sponsorship of research. Faced with a fatal disease, anxiety over side effects might well take second place and be directed chiefly to teratogenicity. When in 1922 the Trevethin Committee endorsed the widespread sale of prophylactic kits, its recommendation was shelved on the ground that protection was less than 100%.
HTLV-llI positive individuals, many of them infected by blood products, transfusion or tattooing, and their spouses, would certainly settle for some effective protection in addition to the condom rather than none. Protection at the site of infection is, moreover, not disease specific: it might be directed now at AIDS and at any future intractable STD which may appear, but prove incidentally to have cut down the incidence of STDs in general, an uncovenanted benefit, which the inventors ofborated vaseline
